

Medical Psilocybin Propagation Committee Meeting minutes

Location: Virtual

Date: February 18, 2026

Time: 3:00 pm to 5:00 pm

Minute Taker: Adrian Estrada, DOH

**This meeting was recorded. For specific details pertaining to the meeting, please refer to the recording located on the Medical Psilocybin Advisory Board Website: [Psilocybin Advisory Board](#)*

Agenda items

1. Opening Statements

Dominick opened the meeting and reminded attendees the session was recorded and publicly posted. Cameras remained off to manage bandwidth and ensure appropriate meeting environments. Chair Chris Peskuski thanked participants and opened with a moment of silence.

2. Introductions

Participants introduced themselves, affiliations, and geographic connections to New Mexico. Introductions included representatives from mycology organizations, policy groups, research backgrounds, and community stakeholders.

3. Review of Agenda

Agenda reviewed and accepted.

4. Propagation Outline Discussion

a. Preparation and Handling

Discussion focused on ensuring safe handling standards aligned with food safety frameworks when material is converted into ingestible products.

b. Labeling and Packaging

Committee reviewed required packaging elements including:

- Sealed and labeled products
- English language labeling (additional languages optional)
- Producer name and permit number

- Species identification
- Net quantity using metric units
- Potency expressed in milligrams based on laboratory results
- Total psilocybin equivalent or total potential psilocybin
- Department issued product identifier and track and trace number
- Expiration date
- Required health and safety statements

Required warnings include:

- Keep out of reach of children
- Do not operate vehicles or machinery while under use
- Risks, benefits, and effects not fully understood

c. Product Information Document

A separate product information document must accompany products and include:

- Laboratory testing results for homogenized batch
- Date of Homogenization
- Growth medium description and inputs
- Manufacturing or processing date
- Ingredient listing by weight or volume
- Allergen disclosures
- Intended use and directions
- Storage instructions
- FDA disclaimer language
- Poison control contact information

This document may be electronic.

d. Traceability (Tracking)

End to end tracking required from cultivation through final product using Department approved systems. Records retained for regulatory period.

e. Compliance

Compliance authority identified as:

- Department of Health
- New Mexico Department of Agriculture for applicable permits
- Local building and environmental health departments

Clear corrective pathways established prior to suspension or revocation.

5. Residency and Commerce Clause Discussion

Significant discussion occurred regarding whether residency requirements could be imposed.

Key points:

- Legal interpretation indicates residency restrictions may conflict with Dormant Commerce Clause principles.
- Some members expressed concern about protecting New Mexico growers.
- Alternatives discussed included incentive programs or disclosure requirements rather than restrictions.
- Department noted resource limitations for implementing financial incentive programs.
- No final residency requirement adopted.

6. Licensing and Permitting Considerations

Permits issued once applicants meet requirements including application review and site inspections. Local zoning compliance remains responsibility of the applicant within municipal regulations.

7. Food Preparation Applicability

Any conversion of raw material into ingestible products falls under food safety oversight. No exemption from standard food safety regulations. Environmental Health and Food Safety training requirements apply.

Consensus reached to include this applicability.

8. Labeling, Packaging, and Traceability Section Approval

Committee approved moving forward with proposed framework while leaving flexibility for refinement as rules develop.

Discussion included whether to present:

- Individual analyte values
- Total alkaloid or equivalent measures

Further evaluation was deferred to dosage and research committees.

9. Transportation

Transportation must maintain secure chain of custody. Transfer is allowed via manifest or authorized contractor pickup if documented. Transportation approach approved by consensus.

10. Definitions Reviewed

Draft definitions discussed for inclusion in rule language, including:

- Contamination
- Facility
- Harvest
- Lot
- Licensed premises
- Producer
- Production
- Psilocybin product
- Recall
- Release for transfer
- Segregate
- Testing
- Waste

These definitions align terminology with regulatory structure.

11. Public Comment Process

Written public comment instructions reiterated:

- Submit to medical.psilocybin@doh.nm.gov
- Include committee name in subject line
- Provide accessible links rather than attachments
- Maximum three pages
- Include full legal name and affiliations
- Deadline 5:00 PM the day following the meeting

12. Rulemaking Timeline Overview

Department outlined anticipated rulemaking process:

- Draft rules submitted to New Mexico Register
- Public comment period minimum 30 days
- Public hearing conducted
- Hearing officer report returned to Department
- Rules promulgated after review
- Potential additional hearing if major revisions are required

Members acknowledged programs in other states required iterative adjustment after launch.

13. Next Steps

Advisory Board review to follow. Committee discussions will continue refining operational details, especially dosage standards and testing interpretation.

Adjournment:

Meeting adjourned at 4:58 PM.

Attendance

Medical Psilocybin Propagation Committee

February 18, 2026

Chair

Chris Peskuski

DOH Staff

Adrian Estrada, DOH

Jonathan Mouchet, DOH

Brenda Martinez, DOH

Dominick Zurlo, DOH

Robert Truckner, DOH

Ismail Zoutat, DOH

Raymond Gallegos, DOH

Participants and Public Attendees

Chris Guest

Denali Wilson

Joshua Kappel

Lisa Ginzburg

Coeli Dwivedi

Ash Shelton

Estevan Hernandez

James Blackford

Jim Dodson

Jim Eslick

Debbie Traynor

Donna Jojola

Catherine Sanchez

Del Potter


Matthew Armstrong

Gregory Evans
Brandon Lopez


Propagation Committee Chat

How to raise your hand to speak:

- If on a computer – click on the “hand” icon near the top of the Teams window (it says “Raise” under the icon)



- If on the Teams app on a phone, please press the ellipses (three dots) in the menu and then the “hand” icon will appear, and you can select it



- If you are joining through voice only on a phone, press *5 to raise or lower your hand

How to Unmute:

- Once your name is called, you will be able to unmute:
- To unmute/mute on Teams on a Computer or on the Teams Phone App click on the microphone icon:



- On a computer it is in the upper right area of the Teams window.
- On a phone it is usually in the lower left of the Teams App, however, different models of phone (Apple, Android, etc...) may have the mute/unmute icon in a different location:
- Telephone: voice only - press *6 to unmute/mute

If you are not able to speak or unmute for any reason and would like to introduce yourself, you may put your information in the chat.

unmute is unavailable

unmute is grayed out

no

ok

You also may not have a mic connected

might have to click on the dropdown beside the microphone icon and select the device

1. Opening statements

2. Introductions

3. Review agenda

4. Propagation Outline

a) Preparation and Handling

b) Labeling and packaging

c) Traceability (tracking)

d) Compliance

e) Sunset Alternatives

5. Other business & discussion

6. Next meetings

a) 3/11/2026 hybrid Albuquerque

3/18/2026 hybrid in Santa Fe

Hello. My name is Matthew. I am an Ojibwe descendant out in East New Mexico. I am here to serve on the subcommittee. I am not affiliated with any formal business.

yes

still grayed out

ok

Jim Dodson

still grayed out

A greyed-out microphone in Microsoft Teams is usually caused by restricted OS permissions, browser restrictions, or audio drivers not initializing properly. Immediately check **Windows Settings > Privacy > Microphone** to ensure "Allow apps to access your microphone" and Teams are enabled.



Key Troubleshooting Steps:

- **Check Windows Permissions:** Go to Settings > Privacy & Security > Microphone. Ensure Microphone access is ON, "Let apps access your microphone" is ON, and Microsoft Teams has permission.
- **Restart Teams:** Fully close and reopen the Teams application to refresh settings.

- **Toggle Hardware:** If using an external mic/headset, unplug and replug it, or ensure it's not physically muted.
- **Check Browser Settings (if using web version):** Click the lock icon in the address bar to ensure microphone access is permitted.
- **Update Drivers/App:** Ensure audio drivers and the Teams app are fully updated.
- **Check Meeting Settings:** In a meeting, click ... (More) > Device settings to select the correct microphone.

If the issue persists, reinstalling Teams or checking for Windows system updates may resolve it.



Microsoft Community Hub +6

Missed the intros/ roll call - my last meeting ran late

Gregory Evans

Independent researcher and home mycologist with no affiliations

Santa Fe resident

My intention is to support the program's development through committee recommendations aligned with emerging research and best practices.

[Variscite NY Four, LLC v. New York State Cannabis Control Board, No. 24-384 \(2d Cir. 2025\)](#)
:: Justia

[PERIDOT TREE WA, INC. v. WASHINGTON STATE LIQUOR AND CANNABIS CONTROL BOARD, No. 24-3481 \(9th Cir. ...\)](#)

Northeast Patients Group v. United Cannabis Patients & Caregivers of Maine, No. 21-1719
(1st Cir. 2...

doesnt the bill mandate that psilocybin be grown in the state?

From my understanding, incentives dont have to be strictly financial, couldn't this be applied as priority for licensing? Or reduced program fees?

What if permits for residents are free and out of state would cost \$\$\$\$\$

the proposed residency program is talking to the personal residency of the principals of say a company? not the age of say a company established in NM? is that right?

if nm follows the same trend as oregon then the whole market for a year is going to be less than 2kg a year. tiny financial insentive for out of state companies to start a business here.

would the state be interested in someone local donating the mushrooms?

motion to table

guided by the invisible hand

VII. Food Preparation and Product Handling

A. Applicability

- Any conversion of raw material into ingestible or prepared products subject to food safety oversight.
- Environmental Health / Food Safety Divisions
 - Food safety and handling training/certification
- No exemption from standard food safety requirements.

two questions: I don't see any particular criteria as to what would be approved as a grow site, for example, does it have to be a standalone building, is a space in a home considered adequate for a grow space that would qualify for a permit or would that be an automatic denial, It would be good to have what would be an acceptable site explained so that could be another check mark that a grower could prepare for as I don't see anything in the current doc that specifies that other than a secure location to store product

sorry that was the one question the other was answered as I was typing

for example in curry county home grow is okay and not subject to the fda guidelines

would have to have a certified kitchen based on abq regs

gotcha, okay thank you, so it would fall back to locality, thank you

we in curry county have it easier than ABQ with the homemade food act we aren't subject to what you guys are

There is very little room for differentiation in mushroom cultivation. Mushrooms are essentially a commodity. Forgive my lack of familiarity with the proposal but will NM allow extracted product and if they do, what will be allowed in terms of isolation of particular actives, formulation and delivery? Psilocin offers advantages over psilocybin in terms of reduced nausea affecting about 35% of users. As far as far as food type products go, will

sublingually delivered products that also offer advantages in terms of reduced adverse effects be allowed?

A. Applicability

- Any conversion of raw material into ingestible or prepared products subject to food safety oversight.
- Environmental Health / Food Safety Divisions
 - Food safety and handling training/certification
- No exemption from standard food safety requirements.

as long as 7 would default to local regulations of where the growers live

VIII. Labeling, Packaging, and Traceability (tracking)

A. Packaging

- Sealed
- Labeled
 - Contain all required information in a legible font at least eight points.
 - Be in English, though it may also be provided in other languages.
 - Be unobstructed and clearly visible.
- The producer's business name and permit number.
- The type of product (ie, homogenized fungi)
- The species name of the fungi
- The net quantity of contents using the metric system of measurement
- The potency of psilocybin analytes contained in the product, expressed in milligrams, and calculated using laboratory test results.
- Total Potential Psilocyn (report both or one of TPP or TPE)
- Total Psilocybin Equivalent
- A logo designed and provided by the department that notifies a reasonable person that the product contains psilocybin that is no smaller than 1/2 inch by 1/2 inch.
- A unique identification number of the product lot, and the state track and trace system number or identifier associated with the product;-
- The expiration date; and,

- The statement: “The risks, benefits, drug interactions, and effects of psilocybin are not fully understood. Individual results may vary.”
- The statement “Keep out of the reach of children.
- The statement “Do not drive a motor vehicle or operate machinery while under the use of psilocybin.”

B. Required Label Elements

- The label must be printed or affixed on the product package and must include:

C. Product Information Document

- A product information document must be available that lists the following information in English on a printed or electronic document in 12-point font or larger:
- All of the requirements for the product label;
- A statement regarding the number of years the business has been established in New Mexico and a statement declaring the state and country of residency, including length of time, of their primary investors;
-
- Results of all laboratory tests conducted on the homogenized batch;
- Date of homogenization;
- The type and composition of the growth medium used, including type of grain, soil, compost, pesticides, and other inputs;
- Date of manufacture or processing of the final product;
- List of all active and inactive ingredients in descending order of predominance by weight or volume;
- Growth medium used;
- List of potential major food allergens which might be contained in the product or in the growth medium;
- Identify the intended use and directions for use; and,
- A description of how the product should be stored;
- The following statement: “This product is not approved by the FDA to treat, cure, or prevent any disease. FDA has not evaluated this product for safety, effectiveness, and quality. There may be long term adverse health effects from consumption of psilocybin, including additional risks for women who are or may become pregnant or are breastfeeding.”
- The New Mexico poison and drug information center phone number;

Does grinded 'mushroom' powder consist only of the fruiting body, or does it include the mycelium as well?

- The net quantity of contents using the metric system of measurement

would recommend to rephrase that to all alkaloids as deemed required by the program

Would this be a strictly "white label" program, or would unique branding/design elements be permitted?

Which specific strains of psilocybin mushrooms are legally permitted for licensed production under current regulations?

any psilocybin producing mushroom is the language in the regs

noted Dominick - rescinded and deferred to sect c

The capsule

would the DOH produce an example label so growers don't interpret everything that is required on the label incorrectly, I don't think any growers would mind putting anything required but would want to be sure they are doing it correctly

D. Traceability (tracking)

- Utilize online tracking system as required by the Department
- End-to-end batch tracking from cultivation through final product
 - Steps for grow, harvest, processing, testing, transport/sale.
- Records retained for a defined regulatory period (5 years)

James Blackford

would the DOH produce an example label so growers don't interpret everything that is required on the label incorrectly, I don't think any growers would mind putting anything required but would want to be sure they are doing it correctly

Yes, there would be a "sample" label.

as far as capsules go, i know there is vegan and non vegan, would there be any reg on this or would it have to be stated as to what type of capsule it is?

James Blackford

as far as capsules go, i know there is vegan and non vegan, would there be any reg on this or would it have to be stated as to what type of capsule it is?

it should be stated (great point)

- Ensure the facilitator provides this information for the label and the product information document for the patient.

if there is not a cost increase in testing for both, this would be a non issue to do both?

- Potency Testing
 - Psilocin
 - Psilocybin
 - ♣ Baeocystin, norbaeocystin and aeruginascin

mg per capsule with total weight per package

Motion to adopt with that language as is deferring details to dosage committee guidance.

Quick question chris

Fantastic, thank you Dominick!

IX. Compliance

- Compliance authority:
 - The Department
 - NMDA for applicable permits
 - Local building and health departments/inspectors for local permits
- Clear corrective action pathways prior to license suspension or revocation.

Really appreciate the 2nd bullet here, compliance will be a learned process for most applicants 😊

but if you don't open the box, is there a cat in there

****Transportation** needs to be done in safe and secure way.

Ensure can meet with others (ie, contractors) or allow for pick-up so long as there is a chain of custody form (ie, manifest).

as long as definitions reflect the changes we have made, such as what is determined to be a batch

“Contamination”. means the presence of microbial, chemical, or physical substances not intended to be part of a psilocybin product and that may pose a risk to patient safety or product integrity, including but not limited to pathogenic microorganisms, mycotoxins, heavy metals, pesticides, solvents, or foreign matter.

“Facility”. means any building, space, or grounds licensed for the cultivation, harvesting, drying, storage, or preparation of psilocybin-producing fungi or psilocybin products, and subject to inspection and regulation by the Department.

"Harvest". means the act of removing psilocybin-producing fungi from a production environment for drying, processing, or storage.

“Lot”. means an identified portion of a batch that is uniform and intended to meet specifications for identity, strength, purity, and composition, and that may be subject to testing, quarantine, or recall.

“Licensed premises”. means the specific facility or facilities identified in a producer’s license application and approved by the Department, within which the producer is authorized to conduct regulated activities.

“Producer”. means a person or entity licensed by the Department to cultivate, harvest, dry, store, and prepare psilocybin-producing fungi or psilocybin products for authorized transfer within the Medical Psilocybin Program.

“Produce” or “Production”. means to engage in any activity related to the cultivation, harvesting, drying, storage, or preparation of psilocybin-producing fungi or psilocybin products.

“Psilocybin product”. means psilocybin-producing fungi, mycelium,[G-1] or preparations derived therefrom that are intended for patient use and contain a detectable amount of psilocybin or psilocin.

“Recall”. means an action taken to remove a psilocybin product from distribution or use after the discovery of a contamination, mislabeling, or other condition that may pose a risk to patient safety.

"Release for transfer" means the point at which a psilocybin product has satisfied applicable testing and quality assurance requirements and may be transferred to another licensed entity.

“Segregate”. means to separate and withhold from transfer or use a batch or lot of psilocybin-producing fungi or psilocybin products pending testing, investigation, or corrective action.

“Testing”. means laboratory analysis of psilocybin-producing fungi or psilocybin products for potency, identity, and the presence of contaminants, conducted by a laboratory approved or licensed by the Department.

“Waste[G-2]” or “Wastage”. means psilocybin-producing fungi, psilocybin products, or related material that is destroyed, discarded, or otherwise rendered unusable in accordance with Department rules.

[G-1]In section II "Mycelial biomass products are prohibited.", but here it is included in the definition of Psilocybin Product

[G-2]Is there any conversation around what happens with waste or discard? Before entering the release phase and while in the release phase (such as when product expires)? or is this for later implementation?

as long as definitions reflect the changes we have made, such as what is determined to be a batch



recommend strike mycelium from psilocybin product

(no need to pause the meeting for this, just want it out there for consideration) the capsules have to be bought by the grower, each one can hold a certain amount, so if a grower buys a lot of capsules that can hold .20mg but the dosage is set in increments of .25mg the homogenized product would essentially have to be moved to a capsule that can hold .25mg or even .50 mg with not only different capsules but also the equipment to incorporate the homogenized mushroom into the capsule, each different size capsule requires different equipment to hold that size and capsule the product, but I'm okay with

everything so far, just a concern I wanted to put out there for growers and the equipment they would have to buy to capsule the correct dosage, a standard for weight in mg would help growers not buy extra equipment and incur potential financial waste

sounds good, thank you thank you

A few definitions to consider.

- **"Homogenization"** - required in V.B, tested in VI.B, but undefined.
- **"Transfer" / "Authorized transfer"** - used in the Producer definition and implied throughout, never defined.
- **"Handler" / "Preparation"** - VII invokes food preparation but defines neither the actor nor the activity.
- **"Department"** - used 20+ times, never formally defined. Minor, but standard in regulatory drafting.

not intended so slow this meeting, just note that they will come up

all good

Congrats Chris and "Department" this is a huge milestone.

How to submit written public comments:

- Please send written public comment to the program email at: medical.psilocybin@doh.nm.gov and include the committee's name in the subject line.
- If referencing documents from other sources/websites:
 - Do not include the document, only a working - accessible hyperlink;

- o Documents must be sent with context provided (i.e. do not simply send a research article);
- The comment must relate to the topics discussed in the meeting.
- Documents are limited to no more than 3 pages (letter size) in length and must be in 10-point font or larger.
- Please remember to include your full, legal name and any organizational affiliations you may be representing (if any) on the documents.
- To be included, please send your comment by 5:00 PM the day after the meeting.

what is the ballpark month for permits to be available if there is no pushback would you estimate? I know there was concern brought up earlier as it takes time from inoculation to harvest , so that all is ready for December



I will definitely be in ABQ on the 11th 😊

Thank you all!! So exciting!!

PENDING FINAL APPROVAL